Md Saifur Rahman Khan

Has grant

Director, Bioinformatics and Metabolomics Unit, The Center for Immunometabolism

University of Pittsburgh
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes

Open Date: 2019-06-01

Close Date:

Grant: Close

Transition of type 2 diabetes from gestational diabetes mellitus: Prediction with high discrimination and novel insight of the type 2 diabetes etiology

Open Date: 2017-08-01

Close Date: 2020-07-01

Grant: Close

Mode of action of isoniazid

Open Date: 2015-09-01

Close Date:

Grant: Close

Mechanism of isoniazid-induced agranulocytosis using omics platforms

Open Date: 2012-09-01

Close Date: 2015-08-01

Grant: Close

NA

Open Date: 2011-09-01

Close Date: 2013-08-01

Articles (4)

Gestational diabetes mellitus (GDM), a transient form of diabetes that resolves postpartum, is a major risk factor for type 2 diabetes (T2D) in women. While the progression from GDM to T2D is not fully understood, it involves both genetic and environmental components. By integrating clinical, metabolomic, and genome-wide association study (GWAS) data, we identified associations between decreased sphingolipid biosynthesis and future T2D, in part through the rs267738 allele of the CERS2 gene in Hispanic women shortly after a GDM pregnancy. To understand the impact of the CERS2 gene and risk allele on glucose regulation, we examined whole-body Cers2 knockout and rs267738 knock-in mice. Both models exhibited glucose intolerance and impaired insulin secretion in vivo. Islets isolated from these models also demonstrated reduced β cell function, as shown by decreased insulin secretion ex vivo. Overall, reduced circulating sphingolipids may indicate a high risk of GDM-to-T2D progression and reflect deficits in CERS2 activity that negatively affect glucose homeostasis and β cell function.

Year:

2025

Aims Gestational diabetes mellitus (GDM) poses a significant risk for developing type 2 diabetes mellitus (T2D) and exhibits heterogeneity. However, understanding the link between different types of post‐GDM individuals without diabetes and their progression to T2D is crucial to advance personalised medicine approaches. Materials and Methods We employed a discovery‐based unsupervised machine learning clustering method to generate clustering models for analysing metabolomics, clinical, and biochemical datasets. For this analysis, we selected 225 women who later developed T2D during the 12‐year follow‐up period from the cohort of 1010 women who returned to a non‐diabetic state at 6–9 weeks (study baseline) after a GDM pregnancy based on 2‐h 75 g research OGTTs. The optimal model was selected by assessing Bayesian Information Criterion values, class separation performance, and the potential for clinically distinguishable clusters, accounting for participant prenatal and early postpartum characteristics. Results The selected model comprises three clusters: pancreatic beta cell dysfunction (cluster‐β: median HOMA‐B 161.3 and median HOMA‐IR 3.8), insulin‐resistance (cluster‐IR: median HOMA‐B 630.5 and median HOMA‐IR 16.8), and a mixed cluster (cluster‐mixed: median HOMA‐B 307.2 and median HOMA‐IR 8.6). These clusters are distinguishable based on postpartum blood test parameters such as glucose tolerance, HOMA indices, and fasting lipid profiles including triglycerides, leptin, HDL‐c, and adiponectin, as well as participant age and BMI. Metabolomic analysis identified unique molecular signatures for each cluster. However, the time to T2D onset was not statistically significant among the three clusters ( p = 0.22). Conclusion This study enhances our understanding of the heterogeneity of early postpartum metabolic profiles that characterise the future onset of T2D diabetes in a diverse cohort of women with GDM, revealing insights into distinct mechanisms and personalised intervention strategies for the prevention of T2D.

Year:

2025

Year:

2023

Year:

2023

Collaborators (4)

Babak Razani

Chief of Cardiology

VA Pittsburgh Healthcare System

UNITED STATES
View details

Julie Van

University of Toronto

CANADA
View details

Scott Summers

Co-Director

University of Utah

UNITED STATES
View details

Michael B Wheeler

Professor

University of Toronto

CANADA
View details